Metabolomics-Based Clinical Efficacy and Effect on the Endogenous Metabolites of Tangzhiqing Tablet, a Chinese Patent Medicine for Type 2 Diabetes Mellitus with Hypertriglyceridemia

Table 1

The comparison of baseline characteristics among three groups (mean ± S.D.).

Variable	TZQ-F Group	Placebo Group	Acarbose Group
	(n=15)	(n=15)	(n=16)
Sex (M/F)	8/7	12/3	9/7
Age (year)	62.93±6.11	57.40±9.74	58.07±5.23
BMI (kg/m2)	26.99±3.17	28.56±3.87	25.90±2.27
Waistline (cm)	95.43±11.24	100.23±8.36	94.87±8.44
HbA1c (%)	7.64±0.81	7.59±1.03	7.25±0.79
FINS (mIU/L)	16.64±8.65	15.00±7.07	15.10±14.57
FBG (mmol/L)	7.44±1.17	7.75±1.07	7.62±1.17
OGTT2hBG (mmol/L)	13.96±4.02	13.76±3.15	13.91±4.68
TG (mmol/L)	1.52±0.61	2.06±1.05	2.35±1.38
TC (mmol/L)	4.92±0.70	4.87±0.82	4.74±0.78
LDL-C (mmol/L)	2.86±0.52	2.87±0.61	2.59±0.63
HDL-C (mmol/L)	1.38±0.39	1.17±0.25	1.22±0.35

Note: data were analyzed using ANOVA. p>0.05 (among three groups). FBG: fasting blood glucose; OGTT 2hBG: oral glucose tolerance test 2 h blood glucose; HbA1c: glycosylated hemoglobin; BMI: body mass index; TC: total cholesterol; TG: triglyceride; HDL: high-density lipoprotein cholesterol; LDL: low-density lipoprotein cholesterol.